Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Toluwalase Awoyemi, DPhil student in Nuffield Department of Women's & Reproductive Health, is recognised with an Africa 35.35 Award - a celebration of the top 35 leading young changemakers under 35 in Africa in 2020.

Toluwalase Awoyemi talking to a group of students in Nigeria

35 young changemakers from Africa and the diaspora hailing from 24 countries made it to the list of the Africa 35.35 Awards celebrating African youth and afro-diaspora excellence.

The Africa 35.35 Awards have announced the 35 under 35 most inspiring young personalities in Africa. It is a prestigious list of 35 young personalities aged 18 to 35 who stand out in Africa and around the world.

Selected from more than 500 applicants, these young people living in Africa and in the Diaspora are credited with exceptional achievements in their communities.

We are extremely proud to say that one of the winners is Dr Toluwalase Awoyemi, a Rhodes scholar, DPhil student at the Nuffield Department of Women's Reproductive Health, University of Oxford and co-founder of The Ganglion Initiative. This social enterprise aims to improve college admission services and career counseling really early, engaging students in public high schools across Nigeria. It organizes free webinars for admission to foreign scholarships with a fairly remarkable total audience of 2,221 people in the first two editions.

The full story is available on the Nuffield Department of Women's & Reproductive Health website

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.